MA52266A - Procédés et compositions de promédicaments isoindoline-1,3-dione et isoindole utiles pour le traitement du cancer, de la rectocolite hémorragique et de maladies inflammatoires associées - Google Patents

Procédés et compositions de promédicaments isoindoline-1,3-dione et isoindole utiles pour le traitement du cancer, de la rectocolite hémorragique et de maladies inflammatoires associées

Info

Publication number
MA52266A
MA52266A MA052266A MA52266A MA52266A MA 52266 A MA52266 A MA 52266A MA 052266 A MA052266 A MA 052266A MA 52266 A MA52266 A MA 52266A MA 52266 A MA52266 A MA 52266A
Authority
MA
Morocco
Prior art keywords
isoindoline
isoindole
dione
cancer
compositions
Prior art date
Application number
MA052266A
Other languages
English (en)
French (fr)
Inventor
William R Baker
Original Assignee
Amgen Europe Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Europe Gmbh filed Critical Amgen Europe Gmbh
Publication of MA52266A publication Critical patent/MA52266A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
MA052266A 2018-03-07 2019-03-06 Procédés et compositions de promédicaments isoindoline-1,3-dione et isoindole utiles pour le traitement du cancer, de la rectocolite hémorragique et de maladies inflammatoires associées MA52266A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862639650P 2018-03-07 2018-03-07

Publications (1)

Publication Number Publication Date
MA52266A true MA52266A (fr) 2021-01-13

Family

ID=65894963

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052266A MA52266A (fr) 2018-03-07 2019-03-06 Procédés et compositions de promédicaments isoindoline-1,3-dione et isoindole utiles pour le traitement du cancer, de la rectocolite hémorragique et de maladies inflammatoires associées

Country Status (11)

Country Link
US (1) US11639332B2 (cg-RX-API-DMAC10.html)
EP (1) EP3762365B1 (cg-RX-API-DMAC10.html)
JP (1) JP7396991B2 (cg-RX-API-DMAC10.html)
AR (1) AR114666A1 (cg-RX-API-DMAC10.html)
AU (1) AU2019229583B2 (cg-RX-API-DMAC10.html)
CA (1) CA3093196A1 (cg-RX-API-DMAC10.html)
ES (1) ES2987705T3 (cg-RX-API-DMAC10.html)
MA (1) MA52266A (cg-RX-API-DMAC10.html)
MX (1) MX2020009288A (cg-RX-API-DMAC10.html)
TW (1) TW202000646A (cg-RX-API-DMAC10.html)
WO (1) WO2019170750A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118370746A (zh) * 2024-04-25 2024-07-23 江苏省中医院 马尿酸在制备溃疡性结肠炎治疗药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472965A (en) 1949-06-14 Metallized tetrakisazo dyes
US3951943A (en) 1974-03-18 1976-04-20 Chemetron Corporation Coupling process in the preparation of disazo diimides
EP0856562A1 (en) 1997-01-31 1998-08-05 Hodogaya Chemical Co Ltd Recording liquid and novel metal complex compound contained therein
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
KR20030026936A (ko) * 2000-06-29 2003-04-03 니폰 가야꾸 가부시끼가이샤 색소증감 광전 변환소자
US7842662B2 (en) * 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
AU2008270363A1 (en) * 2007-06-29 2009-01-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Targeting diazo prodrugs for the treatment of gastrointestinal diseases
DK2276483T3 (da) 2008-03-27 2014-06-10 Celgene Corp Faste former, omfattende (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindolin-1,3-dion, sammensætninger deraf og anvendelser deraf
WO2012083153A1 (en) * 2010-12-16 2012-06-21 Nektar Therapeutics Oligomer-containing apremilast moiety compounds
ES2673114T3 (es) 2011-01-10 2018-06-19 Celgene Corporation Derivados de fenetilsulfona isoindolina como inhibidores de PDE 4 y/o citoquinas

Also Published As

Publication number Publication date
ES2987705T3 (es) 2024-11-15
JP7396991B2 (ja) 2023-12-12
JP2021517134A (ja) 2021-07-15
AR114666A1 (es) 2020-09-30
EP3762365B1 (en) 2024-02-21
AU2019229583B2 (en) 2024-06-13
US11639332B2 (en) 2023-05-02
AU2019229583A1 (en) 2020-09-10
TW202000646A (zh) 2020-01-01
US20200392082A1 (en) 2020-12-17
CA3093196A1 (en) 2019-09-12
MX2020009288A (es) 2020-09-28
EP3762365A1 (en) 2021-01-13
WO2019170750A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
EP3947715A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3894392A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
EP3866781A4 (en) NOVEL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP3908601A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3937932A4 (en) CGAS INHIBITORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER METASTASIS
EP3645739A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF MELANOMA
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3743069A4 (en) DEGRADER OF BCL-2 PROTEIN FOR CANCER TREATMENT
EP3890748A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES
EP3555077A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
EP3612215A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF Pneumonia
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP4045036A4 (en) Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
EP3969597A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATPASE-MEDIATED DISEASES
EP3973047A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF LIVER DISEASES
MA53234A (fr) Compositions et procédés d'inhibition de masp-2 pour le traitement de divers troubles et maladies thrombotiques
EP3761970A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
EP3833340A4 (en) COMPOSITIONS AND METHODS OF TREATMENT FOR PRESBYOPIA
EP3866777A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF INFLAMMATORY DISEASES
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
EP3621600A4 (en) METHODS FOR TREATMENT OF RECIDIVING GLIOBLASTOMA (RGBM)
MA47172A (fr) Compositions et procédés de traitement des inflammations intestinales et du cancer du côlon
EP3481958A4 (en) METHOD AND COMPOSITIONS FOR TREATING DISTURBANCES AND DISEASES WITH RDH12
EP3947460A4 (en) MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER